Previously irradiated tissue increases checkpoint inhibitor sensitivity in a breast cancer mouse model

Radiation-associated mammary tumors responded more strongly to checkpoint blockade in previously irradiated tissue, implicating the tumor microenvironment in treatment sensitivity.

KEY POINTS

  • This preclinical study from the University of Wisconsin investigated how previous irradiation of mammary epithelial cells and surrounding tissue influences secondary breast cancer development and sensitivity to immune checkpoint inhibition. Investigators used p53-mutant HC11 mammary epithelial cells, radiation-exposed derivatives (HC11RT), and transplantable tumor lines (T11 and T11RT) in mice, allowing the contributions of irradiated epithelial cells and irradiated stroma to be studied separately.
  • To model previous radiation exposure, mammary epithelial cells received 11 fractions of 2 Gy over approximately 30 days, while mammary fat pads were irradiated with 4 Gy before cell implantation. When nonirradiated HC11 cells were implanted four weeks after stromal irradiation, tumor incidence increased to 40% (4/10 mice) versus 13% (2/15) in sham-irradiated tissue. Irradiating the epithelial cells themselves increased subsequent tumor development to 55% versus 13% in nonirradiated mammary fat pads.
  • Combining epithelial and stromal radiation exposure further increased tumor development. Tumor incidence reached 85% when previously irradiated HC11RT cells were implanted into irradiated mammary fat pads, compared with 35% when only the mammary tissue was irradiated. These observations indicate that radiation-associated tumorigenesis involves changes in both potentially malignant cells and the surrounding tissue environment, rather than DNA damage to epithelial cells alone.
  • Immune checkpoint blockade combined anti-PD-L1 and anti-CTLA-4 antibodies, administered intraperitoneally at 200 μg per antibody per dose. Tumors derived from previously irradiated epithelial cells demonstrated reduced growth following checkpoint inhibition, whereas corresponding tumors derived from nonirradiated epithelial cells showed little response in the initial model, suggesting that previous cellular radiation exposure can modify immune responsiveness.
  • The surrounding tissue environment was critical to this response. When established radiation-associated T11RT tumors were transplanted into previously irradiated mammary fat pads, checkpoint inhibition reduced tumor growth and significantly prolonged survival compared with untreated controls. However, the survival advantage was absent when the same tumor cells grew in nonirradiated mammary tissue; in nonirradiated flank sites, radiation-associated and non-radiation-associated tumors responded similarly to immunotherapy.
  • Molecular profiling identified an altered immunosuppressive microenvironment in previously irradiated tissue, including increased TGF-β expression in tumor and immune cells, particularly CD8+ T cells, and increased PD-L1 expression on CD4+ T cells. Additional changes included higher expression of IL-4, IL-6, FGF1, MYC, ERBB3 and PDGFRA, suggesting interactions between inflammatory signaling, growth pathways and immune evasion that may contribute to both tumor development and checkpoint inhibitor sensitivity.
  • The experimental model does not reproduce the complete biological history of secondary human breast cancers, which may develop decades after fractionated radiotherapy. Stromal irradiation was limited to a single 4-Gy dose, the experiments involved genetically susceptible murine cells, and no clinical patients were studied. The findings therefore support a mechanistic hypothesis rather than establishing that radiation-associated breast cancers respond better to immunotherapy in clinical practice.

CLINICAL TAKEAWAY

Previous radiation exposure may create a distinct tumor microenvironment that increases dependence on immune checkpoint signaling and potentially enhances sensitivity to checkpoint inhibitors. This preclinical evidence suggests that radiation history and the location of a secondary tumor could be relevant to future immunotherapy research, but it does not yet justify different systemic treatment selection for patients with radiation-associated malignancies.

SOURCE

International Journal of Radiation Oncology, Biology, Physics

Browse more research Suggest a correction